Cord mesenchymal stem cell therapy - Beike Biotechnology

Drug Profile

Cord mesenchymal stem cell therapy - Beike Biotechnology

Alternative Names: Human umbilical cord mesenchymal stem cells (hUC-MSC) - Beike Biotechnology; UC-MSC; UC-MSCT; Wharton's Jelly-derived mesenchymal stem cells (WJMSC) - Beike Biotechnology

Latest Information Update: 14 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beike Biotechnology
  • Developer Beike Biotechnology; Chinese PLA General Hospital
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Multiple sclerosis; Myocardial infarction; Spinocerebellar degeneration; Systemic lupus erythematosus
  • No development reported Primary ovarian insufficiency

Most Recent Events

  • 15 Jul 2015 Safety and efficacy data from a phase II trial in patients with Acute Myocardial Infarction released by Beike Biotechnology
  • 13 May 2014 Efficacy and adverse events data from a phase I/II trial in Systemic lupus erythematosus released by Beike Biotechnology ,
  • 13 May 2014 Phase-II clinical trials in Systemic lupus erythematosus in China (IV) before May 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top